Tests minocycline added to standard care after acute stroke
Tests minocycline with standard care in adults with moderate acute stroke.
Plain-language title generated from the registry record
Registry title: Minocycline in Stroke Study at Maimonides
Key facts
- Where
- Brooklyn, United StatesSee the site
- Phase
- Phase 2/3
Where in United States
- Maimonides Medical CenterBrooklyn, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Joyce Chen
- Trial code
- NCT07237048
- Record updated
- 19 March 2026
- Original description
The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.Read full original descriptionShow less
Effect of Oral Minocycline in Patients With Acute Stroke - a Randomized, Open Label, Prospective Trial
The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older.
The main questions it aims to answer are:
1. Does Minocycline improve *National Institutes of Health Stroke Scale* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -*Modified Rankin Scale* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care?
Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality.
Participants will:
1. Be randomly assigned by block to receive either:
Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS *National Institutes of Health Stroke Scale* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses
NIHSS: *National Institutes of Health Stroke Scale*, which is stroke severity scale,
mRS: *Modified Rankin Scale*, which is stroke disability scale
Inclusion criteria; In order to be eligible to participate in this study, an individual must meet all of the following criteria:; Age >/=18; NIHSS 5-20 *National Institutes of Health Stroke Scale*; Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO *(World Health Organization) * guidelines or acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed; The onset of neurological symptoms less than 24 hours; Exclusion criteria; An individual who meets any of the following criteria is excluded from participation in this study:; Clinically stroke is not suspected; Allergic to the Tetracycline group of medications or Intolerance to Minocycline; Pregnancy or suspected pregnancy or breastfeeding; Previous history of intolerance to Minocycline; Acute or chronic renal failure (stage III with GFR *(Glomerular Filtration Rate) * or Creatinine threshold); Any patients with contraindications to undergo CT (Computed Tomography) / MRI (Magnetic Resonance Imaging); Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission; Pre-existing infectious disease requiring antibiotics; Inability to tolerate enteral medications/feeds; Patient/ family refusal.